Iconovo AB (publ), that develops complete inhalation products for a global market, today announced that the European Patent Office (EPO) has provided a Notice of Allowance regarding an additional patent application for the inhaler platform ICOres. ICOres is currently being used in several of Iconovo’s customer projects and this additional patent will bring a longer and improved protection period for customers launching in the future.
This Notice of Allowance from the European Patent Office is further reinforcing the patent protection of Iconovo’s inhalation device, ICOres. Iconovo has already been granted several ICOres patents in the U.S., Europe, China, and Japan.
"The notification from the European Patent Office further strengthens our international intellectual property and increases the value of our product portfolio. This complementary patent can provide our customers with additional protection and market exclusivity when launching ICOres products in the European market," said Dr. Orest Lastow, CTO of Iconovo.
ICOres is a dry powder inhaler similar in handling to AstraZeneca’s best-selling Turbuhaler®. ICOres has an exact dose counter that allows the patient to know exactly how many doses are left. Another advantage is that the inhaler also gives the patient a visual confirmation when a dose has been inhaled correctly, thereby minimising the risk of incorrect handling. ICOres is the only reservoir inhaler that can be filled with up to three different drug substances, a strong competitive advantage as triple products are expected to be the next big area in inhalation therapy.